- Antimicrobial resistance (AMR) is a challenge for modern medicine.
- The risks of AMR extend beyond antibiotics, affecting cancer treatment, R&D in life sciences and more.
- Recognizing AMR as a foundational threat to clinical innovation is a necessary first step, but we must act too – and soon.
Advances in oncology and immunology have transformed patient outcomes. Chemotherapy medicines, stem-cell transplantation, CAR-T cell therapies, biologics and targeted immunomodulators have turned once-fatal conditions into manageable diseases with patients achieving complete remission in some instances. Yet these innovations rest on a largely invisible foundation: the continued availability of effective antimicrobials
That foundation is now eroding. Rising antimicrobial resistance (AMR) is increasingly undermining the safe delivery, effectiveness and scalability of modern medical innovation.
This is not a future risk. So-called ‘superbugs’ are already killing millions of people a year because they are resistant to the medicines once used to treat them. AMR is a present and growing threat to health systems, patients and the life sciences ecosystem alike.
How is antimicrobial resistance affecting modern medicine?
Cancer patients and people receiving immunosuppressive or immunomodulatory therapies face a uniquely high risk of infection. The very treatments designed to control malignancy or inflammatory disease deliberately weaken immune defences, leaving patients vulnerable to bacterial and fungal infections. In these settings, antimicrobials are not an adjunct to care; they are a prerequisite.
Chemotherapy, CAR-T therapies, stem-cell transplantation and many biologics cannot be delivered safely without reliable antibiotics and antifungals for prophylaxis, early treatment of febrile episodes and management of complications. When antimicrobials fail, infections lead to treatment delays, dose reductions or permanent discontinuation. The consequences are stark: disease progression, avoidable morbidity and preventable deaths.
As resistance rises, this critical safeguard is eroding. Standard prophylactic regimens are losing effectiveness. Common infections are becoming harder to treat. Neutropenic sepsis is more dangerous. The therapeutic window for high-risk, high-value interventions is narrowing. In effect, AMR is silently constraining what modern medicine can safely deliver.
AMR is not just a clinical problem – it is a systems risk
The implications extend far beyond individual patients. For health systems, rising infection risk increases length of stay, complexity of care and costs. For pharmaceutical developers, AMR introduces new strategic and operational challenges across the product lifecycle.
Clinical trials in immunocompromised populations become more complex and expensive as infection risk increases, driving protocol amendments, enhanced safety monitoring and delays. In real-world use, higher rates of infection-related adverse events can reduce treatment eligibility, compromise effectiveness and increase discontinuation. Ultimately, the erosion of effective antimicrobial therapy threatens the return on investment for transformative medicines and limits their population-level impact.
Despite this, AMR is still largely treated as a standalone infectious disease issue. Its downstream effects on cancer care, autoimmune disease management and clinical innovation remain under-measured and undervalued in policy and investment decisions.
AMR must be understood not only as a microbial or stewardship problem, but as a strategic threat to the future of modern medicine.
By: World Economic Forum